Alirocumab

Alirocumab is a human monoclonal antibody directed at proprotein convertase subtilisin kexin type 9 (PCSK9) and has been shown to reduce low-density lipoprotein (LDL) cholesterol levels.

What can Sanquin do for you?

  • Measure drug levels of free drug in the serum using an validated ELISA.
  • Measure the immunogenicity of alirocumab.
  • Provide assay reagents or co-develop novel testing strategies.
  • Folllowing ISO, FDA/EMA, RUO guidelines.

Enquire about our drug level and ADA assays by emailing us at [email protected].